Anti-Alpha-synuclein [VH14 (NAC14)], Rabbit IgG-Fc Fusion,

Absolute Antibody

Anti-Alpha-synuclein [VH14 (NAC14)], Rabbit IgG-Fc Fusion,

9

This antibody binds the hydrophobic non-amyloid component (NAC) of alpha-synuclein between amino acids 53-87. More specifically, this antibody showed high binding to linear epitope comprising aa 61-78 of alpha-syn. Alpha-synuclein is a small 140 amino aci

The fusion of a proteasome-targeting PEST motif to this intrabody enhanced the solubility of the nanobody in cytoplasm and significantly enhanced degradation of the target protein, alpha-syn-GFP (PMID: 22929188). The in vivo therapeutic potential of gene therapy for delivery of proteasome-directed nanobodies selectively targeting alpha-syn was evaluated in a synuclein overexpression-based PD model. Post-mortem assessments of the substantia nigra (SN) of Sprague-Dawley rats after intracellular delivery of VH14-PEST showed that it markedly reduced the level of phosphorylated Serine-129 alpha-syn labeling relative to saline-treated animals (PMID: 30155513). A bifunctional antibody generated by fusing VH14 to a proteosome-targeting signal was able to counteract heterologous proteostatic effects of mutant alpha-Syn on mutant huntingtin Exon1 and protect against alpha-Syn toxicity using propidium iodide or Annexin V readouts (PMID: 27824888).

Functional Assay

Research Use Only

Monoclonal

VH14 (NAC14)

SNCA

synuclein alpha

alpha-synuclein; I+/--synuclein; NACP; non A-beta component of AD amyloid; PARK1; PARK4; PD1; synuclein alpha-140; synuclein, alpha (non A4 component of amyloid precursor); truncated alpha synuclein

Rabbit

IgG

Alpha-synuclein

This is a chimeric antibody, developed from the original camelid VHH antibody, specifically engineered for enhanced compatibility with existing reagents, assays, and techniques.

Human

-20°C,2°C to 8°C

12352203